Zevra Q2 Revenue Jumps 53% to $39.7M, Crushing Estimates on MIPLYFFA Launch
ZVRA sits 48% above its 52-week low of $7.16.
Summary
Zevra's Q2 revenue surged 53% year-over-year to $39.66 million, handily beating the $33.88 million consensus, driven by $30.2 million in MIPLYFFA sales for Niemann-Pick disease type C. Net income came in at $8.75 million, a sharp drop from the prior year's one-time gains, but operating expenses fell on lower SG&A. The company also highlighted $9 million in net reimbursements from its global Expanded Access Program. Management expects continued FDA engagement on celiprolol in H2 2026 and is pursuing European approval for arimoclomol. This follows the June publication of positive MIPLYFFA pediatric data and the CMO departure in June, but the strong commercial launch and guidance update overshadow those events. With a market cap around $622 million and a $24.50 analyst price target, the beat and pipeline progress could drive significant re-rating.
At the time of this announcement, ZVRA was trading at $10.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $622.5M. The 52-week trading range was $7.16 to $15.04. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.